[go: up one dir, main page]

WO2024114687A1 - Anticorps anti-tfr1 et leurs utilisations - Google Patents

Anticorps anti-tfr1 et leurs utilisations Download PDF

Info

Publication number
WO2024114687A1
WO2024114687A1 PCT/CN2023/135130 CN2023135130W WO2024114687A1 WO 2024114687 A1 WO2024114687 A1 WO 2024114687A1 CN 2023135130 W CN2023135130 W CN 2023135130W WO 2024114687 A1 WO2024114687 A1 WO 2024114687A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
binding fragment
vhh
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/135130
Other languages
English (en)
Inventor
Yiqing HU
Lijun Zhang
Huizhen ZHAO
Jiawei Yao
Yuelei SHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocytogen Pharmaceuticals Beijing Co Ltd
Original Assignee
Biocytogen Pharmaceuticals Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocytogen Pharmaceuticals Beijing Co Ltd filed Critical Biocytogen Pharmaceuticals Beijing Co Ltd
Priority to CN202380082014.XA priority Critical patent/CN120282983A/zh
Priority to AU2023404617A priority patent/AU2023404617A1/en
Priority to JP2025531723A priority patent/JP2025539455A/ja
Priority to KR1020257018593A priority patent/KR20250114322A/ko
Priority to EP23896831.7A priority patent/EP4626923A1/fr
Publication of WO2024114687A1 publication Critical patent/WO2024114687A1/fr
Priority to IL320972A priority patent/IL320972A/en
Priority to MX2025006221A priority patent/MX2025006221A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • This disclosure relates to anti-TFR1 (transferrin receptor 1) antibodies, antigen-binding fragments, and the uses thereof.
  • TFR1 transferrin receptor 1
  • Therapeutic antibodies are one of the fastest growing classes of therapeutic compounds, rapidly outpacing the growth of small-molecule drugs. For example, monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size of conventional antibodies.
  • the minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH and VL) . The inherent hydrophobic interaction of VH and VL domains limits the stability and solubility of engineered antibodies, often causing aggregation and/or mispairing of V-domains.
  • VHH variable domain
  • Recombinant VHHs are small (15-20 kDa) and strictly monomeric; they bind their target with nM affinity as well as with being stable in a broad pH and temperature ranges. Molecular manipulation is also easier with VHH; this facilitates the production of multivalent formats of monoclonal antibodies compared with conventional recombinant antibodies and their fragments, which is problematic due to aggregation and reduced affinity. Moreover, VHH often binds to epitopes that are less immunogenic for conventional antibodies.
  • the therapeutic antibodies are human or humanized antibodies.
  • the human or humanized antibodies can be generated by humanization of a rodent antibody (e.g., a mouse antibody) or by using phage libraries.
  • rodent antibody e.g., a mouse antibody
  • phage libraries usually cannot produce heavy chain antibodies.
  • heavy chain antibodies are often obtained from camelid heavy chain antibodies.
  • camelid heavy chain antibodies need to be humanized.
  • the humanization process may adversely affect the binding affinity and introduce immunogenic epitopes to the antibodies. Iterative and time-consuming experiments are often required to improve the properties of these antibodies. And in some cases, these antibodies can also be immunogenic in patients, leading to attenuation of their efficacy over time. Therefore, there is a need to develop more forms of antibodies to treat or prevent human diseases.
  • the present disclosure relates to an antibody or antigen-binding fragment thereof that binds to transferrin receptor 1 (TFR1) , comprising: a heavy chain single variable domain (VHH) comprising complementarity determining regions (CDRs) 1, 2, and 3, in some embodiments, the VHH CDR1 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a selected VHH CDR1 amino acid sequence, the VHH CDR2 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a selected VHH CDR2 amino acid sequence, and the VHH CDR3 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a selected VHH CDR3 amino acid sequence; in some embodiments, the selected VHH CDRs 1, 2, and 3 amino
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 1, 2, and 3, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 4, 5, and 6, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 7, 8, and 9, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 10, 11, and 12, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 13, 14, and 15, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 16, 17, and 18, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 19, 20, and 21, respectively;
  • VHH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 22, 23, and 24, respectively.
  • the VHH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the VHH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively. In some embodiments, the VHH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 7, 8, and 9, respectively. In some embodiments, the VHH comprises CDRs 1, 2, 3 with the amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively.
  • the disclosure is related to an antibody or antigen-binding fragment thereof that binds to TFR1 comprising a heavy chain single variable region (VHH) comprising an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a selected VHH sequence
  • the selected VHH sequence is selected from the group consisting of SEQ ID NOs: 25, 26, 27, and 28.
  • the VHH comprises the sequence of SEQ ID NO: 25.
  • the VHH comprises the sequence of SEQ ID NO: 26.
  • the VHH comprises the sequence of SEQ ID NO: 27.
  • the VHH comprises the sequence of SEQ ID NO: 28.
  • the antibody or antigen-binding fragment specifically binds to a human TFR1, a monkey TFR1, a mouse TFR1, or a chimeric TFR1.
  • the antibody or antigen-binding fragment is a human or humanized antibody or antigen-binding fragment thereof.
  • the antibody or antigen-binding fragment is a multi-specific antibody (e.g., a bispecific antibody) .
  • the disclosure is related to an antibody or antigen-binding fragment thereof comprising the VHH CDRs 1, 2, 3, of the antibody or antigen-binding fragment thereof as described herein.
  • the antibody or antigen-binding fragment comprises a human IgG Fc (e.g., a human IgG1 Fc) .
  • the human IgG Fc comprises a non-asparagine residue (e.g., alanine) at position 297 according to EU numbering.
  • the antibody or antigen-binding fragment comprises two or more heavy chain single variable domains.
  • the disclosure is related to a nucleic acid comprising a polynucleotide encoding the antibody or antigen-binding fragment thereof as described herein.
  • the nucleic acid is cDNA.
  • the disclosure is related to a vector comprising one or more of the nucleic acids as described herein.
  • the disclosure is related to a cell comprising the vector as described herein.
  • the cell is a CHO cell.
  • the disclosure is related to a cell comprising one or more of the nucleic acids described herein.
  • the disclosure is related to a method of producing an antibody or an antigen-binding fragment thereof, the method comprising (a) culturing the cell as described herein under conditions sufficient for the cell to produce the antibody or the antigen-binding fragment thereof; and (b) collecting the antibody or the antigen-binding fragment thereof produced by the cell.
  • the disclosure is related to an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof as described herein covalently bound to a therapeutic agent.
  • the therapeutic agent is a cytotoxic or cytostatic agent.
  • the disclosure is related to a method of treating a subject having a brain disease (e.g., a brain cancer) , the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof, or the antibody-drug conjugate as described herein, to the subject.
  • a brain disease e.g., a brain cancer
  • the antibody or antigen-binding fragment thereof, or the antibody-drug conjugate can pass across the blood-brain barrier (BBB) of the subject.
  • BBB blood-brain barrier
  • the disclosure is related to a method of treating a subject having a cancer, the method comprising administering a therapeutically effective amount of a composition comprising the antibody or antigen-binding fragment thereof, or the antibody-drug conjugate as described herein, to the subject.
  • the cancer is brain cancer, lung cancer, gastric cancer, colorectal cancer, liver cancer, ovarian cancer, prostate cancer, leukemia, or breast cancer.
  • the disclosure is related to a method of identifying a subject as having a brain disease (e.g., a brain cancer) , the method comprising detecting a sample collected from the subject as having the brain disease by the antibody or antigen-binding fragment thereof as described herein, thereby identifying the subject as having the brain disease.
  • the sample is a brain parenchyma sample from the subject.
  • the subject described herein is a human subject.
  • the disclosure is related to a method of delivering an agent to cross blood brain barrier, the method comprising administering the agent covalently linked to the antibody or antigen-binding fragment thereof as described herein to the subject.
  • the agent is an antibody or an antibody drug conjugate.
  • the agent is anti-amyloid antibody.
  • the disclosure is related to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof as described herein, and a pharmaceutically acceptable carrier. In one aspect, the disclosure is related to a pharmaceutical composition comprising the antibody drug conjugate as described herein, and a pharmaceutically acceptable carrier.
  • the disclosure is related to an antibody or antigen-binding fragment thereof that cross-competes with the antibody or antigen-binding fragment thereof as described herein.
  • the disclosure provides a method of making an antibody that specifically binds to an antigen.
  • the method involves exposing the animal as described herein to the antigen; obtaining the sequence of (e.g. by sequencing) nucleic acids encoding human heavy chain immunoglobulin variable regions in a cell that expresses a chimeric heavy chain antibody that specifically binds to the antigen; and operably linking in a cell the nucleic acid encoding the human heavy chain immunoglobulin variable region with a nucleic acid encoding a human heavy chain immunoglobulin constant region.
  • the disclosure also relates to an offspring of the non-human mammal.
  • the non-human mammal is a rodent.
  • the non-human mammal is a mouse.
  • the disclosure also provides to a cell including the targeting vector as described herein.
  • the disclosure also relates to a cell (e.g., a stem cell, an embryonic stem cell, an immune cell, a B cell, a T cell, or a hybridoma) or a cell line, or a primary cell culture thereof derived from the non-human mammal or an offspring thereof.
  • the disclosure further relates to the tissue, organ or a culture thereof derived from the non-human mammal or an offspring thereof.
  • the disclosure further relates to the use of the non-human mammal or an offspring thereof, the animal model generated through the method as described herein in the development of a product related to an immunization process, the manufacture of a human antibody, or the model system for research in pharmacology, immunology, microbiology and medicine.
  • FIG. 1 lists CDR sequences of heavy chain variable region of anti-TFR1 antibodies according to Kabat numbering.
  • FIG. 2 lists CDR sequences of heavy chain variable region of anti-TFR1 antibodies according to IMGT numbering.
  • FIG. 3 lists amino acids sequences discussed in the disclosure.
  • FIG. 4A shows the antibody concentration in total brain protein of hTFR1 mice within 72 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , 24G5-N (G5) , or 24C9-N (G6) .
  • FIG. 4B shows the ratio of antibody concentration in brain total protein to serum antibody concentration of hTFR1 mice within 72 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , 24G5-N (G5) , or 24C9-N (G6) .
  • FIG. 4C shows the antibody concentration in brain parenchyma of hTFR1 mice within 72 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , 24G5-N (G5) , or 24C9-N (G6) .
  • FIG. 4D shows the ratio of antibody concentration in brain parenchyma to serum antibody concentration of hTFR1 mice within 72 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , 24G5-N (G5) , or 24C9-N (G6) .
  • FIG. 5A shows the antibody concentration test results in brain parenchyma after 24 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , or 24G5-N (G5) .
  • FIG. 5B shows the antibody concentration test results in brain total protein (Whole Brain) after 24 hours of intravenous (i. v. ) administration of hIgG1 (G1) , JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , or 24G5-N (G5) .
  • FIG. 6 shows the antibody concentration results after 6 hours or 24 hours of intravenous (i.v. ) administration of JR141-N (G2-G4) or 24G5-N (G5-G7) ) .
  • hIgG1 was used as a negative control.
  • FIG. 7 shows the ADC concentration test results in brain parenchyma after 72 hours of intravenous (i. v. ) administration of 24G5-ADC or 24G5-mono-ADC.
  • a heavy-chain antibody is an antibody which has only heavy chains (generally two heavy chains) and lacks the two light chains usually found in antibodies.
  • Naturally occurring heavy-chain antibodies have been discovered in cartilaginous fishes (e.g., shark) and camelids (e.g., llama) .
  • the immunoglobulin new antigen receptor IgNAR
  • IgNAR shows significant structural differences to other antibodies. It has five constant domains (CH) per chain instead of the usual three, several disulfide bonds in unusual positions, and the complementarity-determining region 3 (CDR3) forms an extended loop covering the site which binds to a light chain in other antibodies.
  • camelids such as dromedaries, camels, llamas and alpacas.
  • camelids e.g., llamas
  • camelids can produce conventional antibodies made of two heavy chains and two light chains bound together with disulfide bonds in a Y shape (e.g., IgG1) .
  • IgG1 two unique subclasses of IgG: IgG2 and IgG3, also known as heavy chain IgG.
  • IgG2 and IgG3 also known as heavy chain IgG.
  • These antibodies are made of only two heavy chains, which lack the CH1 region but still bear an antigen-binding domain (e.g., VHH) at their N-terminus.
  • an antigen-binding domain e.g., VHH
  • variable regions from both heavy and light chains to allow a high diversity of antigen-antibody interactions. Although isolated heavy and light chains still show this capacity, they exhibit very low affinity when compared to paired heavy and light chains.
  • the unique feature of heavy chain IgG is the capacity of their monomeric antigen binding regions to bind antigens with specificity, affinity and especially diversity that are comparable to conventional antibodies without the need of pairing with another region. This feature is mainly due to a couple of major variations within the amino acid sequence of the variable region of the two heavy chains, which induce deep conformational changes when compared to conventional Ig. Major substitutions in the variable regions prevent the light chains from binding to the heavy chains, but also prevent unbound heavy chains from being recycled by the Immunoglobulin Binding Protein.
  • VHH single variable domain of these heavy-chain antibodies
  • sdAb single variable domain generated by adaptive immune systems.
  • CDR3 Complementarity Determining Region 3
  • VHHs can extend into crevices on proteins that are not accessible to conventional antibodies, including functionally interesting sites such as the active site of an enzyme or the receptor-binding canyon on a virus surface.
  • an additional cysteine residue allows the structure to be more stable, thus increasing the strength of the interaction.
  • VHHs offer numerous other advantages compared to conventional antibodies carrying variable domains (VH and VL) of conventional antibodies, including higher stability, solubility, expression yields, and refolding capacity, as well as better in vivo tissue penetration. Moreover, in contrast to the VH domains of conventional antibodies, VHH do not display an intrinsic tendency to bind to light chains. This facilitates the induction of heavy chain antibodies in the presence of a functional light chain loci. Further, since VHH do not bind to VL domains, it is much easier to reformat VHHs into bispecific antibody constructs than constructs containing conventional VH-VL pairs or single domains based on VH domains.
  • the CDR3 corresponds to the unique region of the antibody molecule that is encoded by a DNA element newly generated during B-cell development. Genetic recombination results in the fusion of a D-element with flanking V-and J-elements. During recombination further genetic diversity is generated by addition and/or deletion of nucleotides at the junctions. Thereby, the CDR3 loop provides the major contribution to antibody diversity and specificity.
  • variable region genes IGHV, IGHD, and IGHJ
  • IGHV variable region genes
  • antibody refers to any antigen-binding molecule that contains at least one (e.g., one, two, three, four, five, or six) complementary determining region (CDR) (e.g., any of the three CDRs from an immunoglobulin light chain or any of the three CDRs from an immunoglobulin heavy chain) and is capable of specifically binding to an epitope.
  • CDR complementary determining region
  • Non-limiting examples of antibodies include: monoclonal antibodies, polyclonal antibodies, multi-specific antibodies (e.g., bi-specific antibodies) , single-chain antibodies, heavy chain antibodies, chimeric antibodies, human antibodies, and humanized antibodies.
  • an antibody can contain an Fc region of a human antibody.
  • the term antibody also includes derivatives, e.g., bi-specific antibodies, single-chain antibodies, diabodies, linear antibodies, and multi-specific antibodies formed from antibody fragments.
  • the term “antigen-binding fragment” refers to a portion of a full-length antibody, wherein the portion is capable of specifically binding to an antigen.
  • the antigen-binding fragment contains at least one variable domain (e.g., a variable domain of a heavy chain or a variable domain of light chain) .
  • variable domains include, e.g., Fab, Fab’, F (ab’) 2, and Fv fragments.
  • human antibody refers to an antibody that is encoded by a nucleic acid (e.g., rearranged human immunoglobulin heavy or light chain locus) present in a human.
  • a human antibody is collected from a human or produced in a human cell culture (e.g., human hybridoma cells) .
  • a human antibody is produced in a non-human cell (e.g., a mouse or hamster cell line) .
  • a human antibody is produced in a bacterial or yeast cell.
  • a human antibody is produced in a transgenic non-human animal (e.g., a mouse) containing an unrearranged or rearranged human immunoglobulin locus (e.g., heavy or light chain human immunoglobulin locus) .
  • a transgenic non-human animal e.g., a mouse
  • an unrearranged or rearranged human immunoglobulin locus e.g., heavy or light chain human immunoglobulin locus
  • chimeric antibody refers to an antibody that contains a sequence present in at least two different antibodies (e.g., antibodies from two different mammalian species such as a human and a mouse antibody) .
  • a non-limiting example of a chimeric antibody is an antibody containing the variable domain sequences (e.g., all or part of a light chain and/or heavy chain variable domain sequence) of a human antibody and the constant domains of a non-human antibody. Additional examples of chimeric antibodies are described herein and are known in the art.
  • humanized antibody refers to a non-human antibody which contains sequence derived from a non-human (e.g., mouse) immunoglobulin and contains sequences derived from a human immunoglobulin.
  • single-chain antibody refers to a single polypeptide that contains at least two immunoglobulin variable domains (e.g., a variable domain of a mammalian immunoglobulin heavy chain or light chain) that is capable of specifically binding to an antigen.
  • heavy-chain antibody refers to an antibody molecule which is composed only of heavy chains (generally two) and does not have any light chains.
  • VHH refers to the variable domain derived from a heavy-chain antibody.
  • the VHH can specifically recognize an antigen without the need to be paired with a VL.
  • the VHH (also know as sdAb or nanobody) described herein is derived from any of the humanized heavy-chain antibody described herein.
  • the VHH, sdAb, or nanobody described herein is derived from the heavy chain antibody produced by any of the genetically modified non-human animal described herein.
  • the terms “subject” and “patient” are used interchangeably throughout the specification and describe an animal, human or non-human. Veterinary and non-veterinary applications are contemplated by the present disclosure.
  • Human patients can be adult humans or juvenile humans (e.g., humans below the age of 18 years old) .
  • patients include but are not limited to mice, rats, hamsters, guinea-pigs, rabbits, ferrets, cats, dogs, and primates.
  • non-human primates e.g., monkey, chimpanzee, gorilla, and the like
  • rodents e.g., rats, mice, gerbils, hamsters, ferrets, rabbits
  • lagomorphs e.g., swine (e.g., pig, miniature pig)
  • equine canine, feline, bovine, and other domestic, farm, and zoo animals.
  • the phrases “specifically binding” and “specifically binds” mean that the antibody interacts with its target molecule preferably to other molecules, because the interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) on the target molecule; in other words, the reagent is recognizing and binding to molecules that include a specific structure rather than to all molecules in general.
  • An antibody that specifically binds to the target molecule may be referred to as a target-specific antibody.
  • polypeptide, ” “peptide, ” and “protein” are used interchangeably to refer to polymers of amino acids of any length of at least two amino acids.
  • nucleic acid molecule As used herein, the terms “polynucleotide, ” “nucleic acid molecule, ” and “nucleic acid sequence” are used interchangeably herein to refer to polymers of nucleotides of any length of at least two nucleotides, and include, without limitation, DNA, RNA, DNA/RNA hybrids, and modifications thereof.
  • the present disclosure provides antibodies and antigen-binding fragments thereof (e.g., heavy chain antibodies, humanized heavy chain antibodies, or multi-specific antibodies) that are produced by the methods described herein.
  • antibodies and antigen-binding fragments thereof e.g., heavy chain antibodies, humanized heavy chain antibodies, or multi-specific antibodies
  • a non-limiting antibody of the present disclosure can be an intact, four-immunoglobulin-chain antibody comprising two heavy chains and two light chains.
  • the heavy chain of the antibody can be of any isotype including IgM, IgG, IgE, IgA, or IgD or subclasses including IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, etc.
  • the light chain can be a kappa light chain or a lambda light chain.
  • An antibody can comprise two identical copies of a light chain and two identical copies of a heavy chain.
  • the heavy chains which each contain one variable domain (or variable region, V H ) and multiple constant domains (or constant regions) , bind to one another via disulfide bonding within their constant domains to form the “stem” of the antibody.
  • the light chains which each contain one variable domain (or variable region, V L ) and one constant domain (or constant region) , each bind to one heavy chain via disulfide binding.
  • the variable region of each light chain is aligned with the variable region of the heavy chain to which it is bound.
  • the variable regions of both the light chains and heavy chains contain three hypervariable regions sandwiched between more conserved framework regions (FR) .
  • CDRs complementary determining regions
  • the four framework regions largely adopt a beta-sheet conformation and the CDRs form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the CDRs in each chain are held in close proximity by the framework regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding region.
  • the CDRs are important for recognizing an epitope of an antigen.
  • an “epitope” is the smallest portion of a target molecule capable of being specifically bound by the antigen binding domain of an antibody.
  • the minimal size of an epitope may be about three, four, five, six, or seven amino acids, but these amino acids need not be in a consecutive linear sequence of the antigen’s primary structure, as the epitope may depend on an antigen’s three-dimensional configuration based on the antigen’s secondary and tertiary structure.
  • the antibody is an intact immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgG4, IgM, IgD, IgE, IgA) .
  • the IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, differ in their constant region, particularly in their hinges and upper CH2 domains. The sequences and differences of the IgG subclasses are known in the art, and are described, e.g., in Vidarsson, et al, "IgG subclasses and allotypes: from structure to effector functions.
  • the heavy chain constant regions in the heavy chain antibodies can be derived from any immunoglobulin molecules described herein (e.g., IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgG4, IgM, IgD, IgE, IgA) .
  • the antibody can also be an immunoglobulin molecule that is derived from any species (e.g., human, rodent, mouse, rat, camelid) .
  • Antibodies disclosed herein also include, but are not limited to, polyclonal, monoclonal, monospecific, multi-specific antibodies, and chimeric antibodies that include an immunoglobulin binding domain fused to another polypeptide.
  • the term “antigen binding domain” or “antigen binding fragment” is a portion of an antibody that retains specific binding activity of the intact antibody, i.e., any portion of an antibody that is capable of specific binding to an epitope on the intact antibody’s target molecule.
  • an antibody or an antigen binding fragment thereof can be, e.g., a scFv, a Fv, a Fd, a dAb, a bispecific antibody, a bispecific scFv, a diabody, a linear antibody, a single-chain antibody molecule, a multi-specific antibody formed from antibody fragments, and any polypeptide that includes a binding domain which is, or is homologous to, an antibody binding domain.
  • Non-limiting examples of antigen binding domains include, e.g., the heavy chain and/or light chain CDRs of an intact antibody, the heavy and/or light chain variable regions of an intact antibody, full length heavy or light chains of an intact antibody, or an individual CDR from either the heavy chain or the light chain of an intact antibody.
  • the antigen binding fragment can form a part of a chimeric antigen receptor (CAR) .
  • the chimeric antigen receptor are fusions of VHH as described herein, fused to CD3-zeta transmembrane-and endodomain.
  • the antibodies and antigen-binding fragments thereof (e.g., humanized antibodies or chimeric antibodies) that are produced by the methods described herein have various advantages. In some embodiments, no further optimization is required to obtain desired properties (e.g., binding affinities, thermal stabilities, and/or limited aggregation) .
  • the antibody (or antigen-binding fragments thereof) specifically binds to a target with a dissociation rate (koff) of less than 0.1 s -1 , less than 0.01 s -1 , less than 0.001 s -1 , less than 0.0001 s -1 , or less than 0.00001 s -1 .
  • the dissociation rate (koff) is greater than 0.01 s -1 , greater than 0.001 s -1 , greater than 0.0001 s -1 , greater than 0.00001 s -1 , or greater than 0.000001 s -1 .
  • kinetic association rates are greater than 1 x 10 2 /Ms, greater than 1 x 10 3 /Ms, greater than 1 x 10 4 /Ms, greater than 1 x 10 5 /Ms, or greater than 1 x 10 6 /Ms. In some embodiments, kinetic association rates (kon) are less than 1 x 10 5 /Ms, less than 1 x 10 6 /Ms, or less than 1 x 10 7 /Ms.
  • KD is less than 1 x 10 -6 M, less than 1 x 10 -7 M, less than 1 x 10 -8 M, less than 1 x 10 -9 M, or less than 1 x 10 -10 M. In some embodiments, the KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM.
  • KD is greater than 1 x 10 -7 M, greater than 1 x 10 -8 M, greater than 1 x 10 - 9 M, greater than 1 x 10 -10 M, greater than 1 x 10 -11 M, or greater than 1 x 10 -12 M.
  • the antibody binds to a target with KD less than or equal to about 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM.
  • thermal stabilities are determined.
  • the antibodies or antigen binding fragments as described herein can have a Tm greater than 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 °C.
  • substitutions are performed to a parental heavy chain antibody sequence to make a variant heavy chain antibody.
  • a heavy chain antibody variant of a parental heavy chain antibody has an antigen binding affinity that is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%or at least 100% (e.g., at least 150%, at least 200%, at least 500%, at least 1000%, or up to at least 10,000%) of the binding affinity of the parental heavy chain antibody to a particular antigen.
  • a variant heavy chain antibody will comprise a single substitution as compared to a parental heavy chain antibody.
  • the resultant variant heavy chain antibody is tested to confirm that the desired binding affinity and/or specificity has not been significantly decreased by the replacement residues.
  • an improved variant heavy chain antibody is produced by the substitution of amino acids from a different human heavy chain sequence.
  • the VHH is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%identical to a parental VHH.
  • the VHH described herein can be used to make multi-specific (e.g., bispecific antibodies) .
  • the present disclosure provides a multi-specific antibody comprising: a first antigen binding portion and a second antigen binding portion.
  • the first antigen binding portion comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) , wherein the VH and VL together form an antigen-binding site that specifically binds a first epitope.
  • the first antigen binding portion comprises a VHH that specifically binds a first epitope.
  • the second antigen binding portion comprises a VHH that specifically binds a second epitope.
  • the first epitope and the second epitope are from the same antigen.
  • the first epitope and the second epitope are from different antigens.
  • the first antigen binding portion is a full-length antibody consisting of two heavy chains and two light chains. In some embodiments, the first antigen binding portion is an antibody fragment comprising a heavy chain comprising the VH and a light chain comprising the VL. In some embodiments, the second antigen binding portion comprises a single polypeptide chain. In some embodiments, the C terminus of the second antigen binding portion is fused to the N-terminus of at least one heavy chain of the first antigen binding portion. In some embodiments, the C terminus of the second antigen binding portion is fused to the N-terminus of at least one light chain of the first antigen binding portion.
  • the N terminus of the second antigen binding portion is fused to the C-terminus of at least one heavy chain of the first antigen binding portion. In some embodiments, the N terminus of the second antigen binding portion is fused to the C-terminus of at least one light chain of the first antigen binding portion. In some embodiments, the second antigen binding portion is a Fab-like domain comprising a first polypeptide chain comprising a first VHH fused to a CH1 domain, and a second polypeptide chain comprising a second VHH fused to a CL domain.
  • the antibody or antigen-binding fragment thereof is a tri-specific antibody.
  • the tri-specific antibody is a tri-specific VHH-Fc.
  • the tri-specific antibody comprises the same VHHs.
  • the tri-specific antibody comprises different VHHs.
  • the VHHs bind to the same epitope. In some embodiments, the VHHs bind to different epitopes.
  • the antibody or antigen-binding fragment thereof has four or more than four VHHs.
  • at least four VHHs are combined without the addition of IgG Fc domain to construct tetra-specific VHHs. These molecules would have the added advantage of increased affinity and avidity towards the antigen compared to bi-and tri-specific VHH-Fcs, despite lacking the Fc effector functions.
  • these the antibody or antigen-binding fragment thereof (e.g., comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10) has a functional Fc.
  • the heavy-chain antibody produced by the genetically modified non-human animal described herein has a VHH domain that includes CDR1, CDR2, and CDR3.
  • the CDR3 length is between 6-23, e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23.
  • the CDR3 length is at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, or at least 23.
  • TFR1 Transferrin receptor 1 (TFR1)
  • TFR1 also known as cluster of differentiation 71 (CD71)
  • CD71 cluster of differentiation 71
  • Tf transferrin
  • Human TFR1 is a 90 kDa type II transmembrane glycoprotein consisting of 760 amino acids that is found as a dimer (180 kDa) linked by disulfide bonds on the cell surface.
  • the TFR1 monomer is composed of a large extracellular, C-terminal domain of 671 amino acids containing the Tf-binding site, a transmembrane domain (28 amino acids) , and an intracellular N-terminal domain (61 amino acids) .
  • the C-terminal extracellular domain contains three N-linked glycosylation sites at asparagine residues 251, 317, and 727 and one O-linked glycosylation site at threonine 104, which are all required for adequate function of the receptor.
  • Transferrin It is an 80 kDa glycoprotein composed of two 40 kDa subunits, known as the N-and C-lobes that are separated by a short linker sequence. Each subunit is capable of binding to one free ferric iron (Fe 3+ ) and thus, Tf may have up to two atoms of iron attached. Tf in its iron free form, apo-Tf, binds Fe 3+ with high efficiency in the blood and transports it to the cell surface for internalization through the interaction with TFR1. As a membrane protein regulating iron import, TFR1 is a member of the TFR family that shows nanomolar affinity to transferrin (Tf) bound to Fe 3+ .
  • Tf-TFR1 The complex of Tf-TFR1 is internalized through endocytosis mediated by clathrin, and Fe 3+ is disassociated from Tf when pH decreases to 5.5. At this pH, apo-Tf and TFR1 are still associated and recycled to cell surface with physiological pH, so the former is released.
  • TFR1 Iron uptake by transferrin receptor is an important way for cancer cells to absorb iron, thus accumulating evidence has proven that TFR1 participated in tumor onset and progression, and its expression was dysregulated significantly in many cancers. The relationship between TFR1 and cancers has been revealed, rendering TFR1 a valuable pharmaceutical target for intervening with cancers.
  • TFR1 expressed on the endothelial cells of the blood-brain barrier is used also in preclinical research to allow the delivery of large molecules including antibodies into the brain.
  • the TFR1 targeting antibodies can cross the blood-brain barrier, without interfering with the uptake of iron.
  • TFR1, Tf, and their functions can be found, e.g., in Candelaria, P.V., et al. "Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. " Frontiers in Immunology 12 (2021) : 607692; and Shen, Y., et al. "Transferrin receptor 1 in cancer: a new sight for cancer therapy. " American Journal of Cancer Research 8.6 (2018) : 916; each of which is incorporated by reference in its entirety.
  • VHH Heavy chain single variable domain
  • Monoclonal and recombinant antibodies are important tools in medicine and biotechnology. Like all mammals, camelids (e.g., llamas) can produce conventional antibodies made of two heavy chains and two light chains bound together with disulfide bonds in a Y shape (e.g., IgG1) . However, they also produce two unique subclasses of IgG: IgG2 and IgG3, also known as heavy chain IgG. These antibodies are made of only two heavy chains, which lack the CH1 region but still bear an antigen-binding domain at their N-terminus called VHH (or nanobody) . Conventional Ig require the association of variable regions from both heavy and light chains to allow a high diversity of antigen-antibody interactions.
  • heavy chain IgG The unique feature of heavy chain IgG is the capacity of their monomeric antigen binding regions to bind antigens with specificity, affinity and especially diversity that are comparable to conventional antibodies without the need of pairing with another region. This feature is mainly due to a couple of major variations within the amino acid sequence of the variable region of the two heavy chains, which induce deep conformational changes when compared to conventional Ig. Major substitutions in the variable regions prevent the light chains from binding to the heavy chains, but also prevent unbound heavy chains from being recycled by the immunoglobulin binding proteins.
  • the single variable domain of these antibodies (designated VHH, sdAb, or nanobody) is the smallest antigen-binding domain generated by adaptive immune systems.
  • the third Complementarity Determining Region (CDR3) of the variable region of these antibodies has been found to be twice as long as the conventional ones. This results in an increased interaction surface with the antigen as well as an increased diversity of antigen-antibody interactions, which compensates the absence of the light chains.
  • CDR3 complementarity-determining region 3
  • VHHs can extend into crevices on proteins that are not accessible to conventional antibodies, including functionally interesting sites such as the active site of an enzyme or the receptor-binding canyon on a virus surface.
  • VHHs offer numerous other advantages compared to conventional antibodies carrying variable domains (VH and VL) of conventional antibodies, including higher stability, solubility, expression yields, and refolding capacity, as well as better in vivo tissue penetration and internalization. Moreover, in contrast to the VH domains of conventional antibodies, VHH do not display an intrinsic tendency to bind to light chains. Since VHH do not bind to VL domains, it is much easier to reformat VHHs into multi-specific (e.g., bispecific antibody) constructs than constructs containing conventional VH-VL pairs or single domains based on VH domains.
  • VH and VL variable domains
  • the disclosure provides e.g., anti-TFR1 antibodies, the modified antibodies thereof, the chimeric antibodies thereof, and the humanized antibodies thereof.
  • the CDR sequences for 23B8, and 23B8 derived antibodies include CDRs of the VHH domain as set forth in SEQ ID NOs: 1, 2, and 3, respectively, as defined by Kabat numbering.
  • the CDRs can also be defined by IMGT system. Under the IMGT numbering, the CDRs of the VHH domain are set forth in SEQ ID NOs: 13, 14, and 15, respectively.
  • the CDR sequences for 24A1, and 24A1 derived antibodies include CDRs of the VHH domain as set forth in SEQ ID NOs: 4, 5, and 6, respectively, as defined by Kabat numbering.
  • the CDRs can also be defined by IMGT system. Under the IMGT numbering, the CDRs of the VHH domain are set forth in SEQ ID NOs: 16, 17, and 18, respectively.
  • the CDR sequences for 24C9, and 24C9 derived antibodies include CDRs of the VHH domain as set forth in SEQ ID NOs: 7, 8, and 9, respectively, as defined by Kabat numbering.
  • the CDRs can also be defined by IMGT system. Under the IMGT numbering, the CDRs of the VHH domain are set forth in SEQ ID NOs: 19, 20, and 21, respectively.
  • the CDR sequences for 24G5, and 24G5 derived antibodies include CDRs of the VHH domain as set forth in SEQ ID NOs: 10, 11, and 12, respectively, as defined by Kabat numbering.
  • the CDRs can also be defined by IMGT system. Under the IMGT numbering, the CDRs of the VHH domain are set forth in SEQ ID NOs: 22, 23, and 24, respectively.
  • the amino acid sequence for the VHH domain of 23B8 antibody is set forth in SEQ ID NO: 25.
  • the amino acid sequence for the VHH domain of 24A1 antibody is set forth in SEQ ID NO: 26.
  • the amino acid sequence for the VHH domain of 24C9 antibody is set forth in SEQ ID NO: 27.
  • the amino acid sequence for the VHH domain of 24G5 antibody is set forth in SEQ ID NO: 28.
  • the amino acid sequences for various modified or humanized VHH are also provided.
  • the VHH domain of a heavy-chain antibody can have more than one version of humanized sequences.
  • the humanized VHH domain is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%identical to any sequence of SEQ ID NOS: 25-28.
  • the antibodies or antigen-binding fragments thereof described herein can also contain one, two, or three VHH domain CDRs selected from the group of SEQ ID NOs: 1-3, SEQ ID NOs: 4-6, SEQ ID NOs: 7-9, SEQ ID NOs: 10-12, SEQ ID NOs: 13-15, SEQ ID NOs: 16-18, SEQ ID NOs: 19-21, and SEQ ID NOs: 22-24.
  • the antibodies can have a heavy chain single variable domain (VHH) comprising complementarity determining regions (CDRs) 1, 2, 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95%identical to a selected VHH CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95%identical to a selected VHH CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90%, or 95%identical to a selected VHH CDR3 amino acid sequence.
  • VHH CDRs 1, 2, 3 amino acid sequences are shown in FIG. 1 and FIG. 2.
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of VHH CDR1 with zero, one or two amino acid insertions, deletions, or substitutions; VHH CDR2 with zero, one or two amino acid insertions, deletions, or substitutions; VHH CDR3 with zero, one or two amino acid insertions, deletions, or substitutions, wherein VHH CDR1, VHH CDR2, and VHH CDR3 are selected from the CDRs in FIG. 3.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 1 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 2 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 3 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 4 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 5 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 6 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 7 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 8 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 9 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 10 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 11 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 12 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 13 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 14 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 15 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 16 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 17 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 18 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 19 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 20 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 21 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the antibody or an antigen-binding fragment described herein can contain a heavy chain single variable domain (VHH) containing one, two, or three of the CDRs of SEQ ID NO: 22 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 23 with zero, one or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 24 with zero, one or two amino acid insertions, deletions, or substitutions.
  • VHH heavy chain single variable domain
  • the insertions, deletions, and substitutions can be within the CDR sequence, or at one or both terminal ends of the CDR sequence.
  • the CDR is determined based on Kabat numbering scheme. In some embodiments, the CDR is determined based on Chothia numbering scheme. In some embodiments, the CDR is determined based on a combination numbering scheme. In some embodiments, the CDR is determined based on IMGT numbering scheme.
  • the disclosure also provides antibodies or antigen-binding fragments thereof that bind to TFR1 (human TFR1) .
  • the antibodies or antigen-binding fragments thereof contain a heavy chain single variable region (VHH) comprising or consisting of an amino acid sequence that is at least 80%, 85%, 90%, or 95%identical to a selected VHH sequence.
  • VHH heavy chain single variable region
  • the selected VHH sequence is SEQ ID NO: 25.
  • the selected VHH sequence is SEQ ID NO: 26.
  • the selected VHH sequence is SEQ ID NO: 27.
  • the selected VHH sequence is SEQ ID NO: 28.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes) .
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • the comparison of sequences and determination of percent identity between two sequences can be accomplished, e.g., using a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
  • the disclosure also provides nucleic acid comprising a polynucleotide encoding a polypeptide comprising an immunoglobulin heavy chain single variable domain (VHH) .
  • VHH comprises CDRs as shown in FIG. 1 and FIG. 2, or has sequences as shown in FIG. 3.
  • the antibodies and antigen-binding fragments can also be antibody variants (including derivatives and conjugates) of antibodies or antibody fragments and multi-specific (e.g., bi-specific) antibodies or antibody fragments.
  • Additional antibodies provided herein are polyclonal, monoclonal, multi-specific (multimeric, e.g., bi-specific) , human antibodies, chimeric antibodies (e.g., human-mouse chimera) , single-chain antibodies, intracellularly-made antibodies (i.e., intrabodies) , and antigen-binding fragments thereof.
  • the antibodies or antigen-binding fragments thereof comprises an Fc domain that can be originated from various types (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) , class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) , or subclass.
  • the Fc domain is originated from an IgG antibody or antigen-binding fragment thereof.
  • the Fc domain comprises one, two, three, four, or more heavy chain constant regions.
  • the present disclosure also provides an antibody or antigen-binding fragment thereof that cross-competes with any antibody or antigen-binding fragment as described herein.
  • the cross-competing assay is known in the art, and is described e.g., in Moore et al., "Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. " Journal of virology 70.3 (1996) : 1863-1872, which is incorporated herein reference in its entirety.
  • the present disclosure also provides an antibody or antigen-binding fragment thereof that binds to the same epitope or region as any antibody or antigen-binding fragment as described herein.
  • the epitope binning assay is known in the art, and is described e.g., in Estep et al. "High throughput solution-based measurement of antibody-antigen affinity and epitope binning. " MAbs. Vol. 5. No. 2. Taylor &Francis, 2013, which is incorporated herein reference in its entirety.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain single variable domain (VHH) CDR1 selected from SEQ ID NOs: 1, 4, 7, 10, 13, 16, 19, and 22.
  • VHH heavy chain single variable domain
  • the antibody or antigen-binding fragment thereof comprises a heavy chain single variable domain (VHH) CDR2 selected from SEQ ID NOs: 2, 5, 8, 11, 14, 17, 20, and 23.
  • VHH heavy chain single variable domain
  • the antibody or antigen-binding fragment thereof comprises a heavy chain single variable domain (VHH) CDR3 selected from SEQ ID NOs: 3, 6, 9, 12, 15, 18, 21, and 24.
  • VHH heavy chain single variable domain
  • TFR1 performs a critical role in cellular iron uptake through the interaction with iron-bound TF. Iron is required for multiple cellular processes and is essential for DNA synthesis and, thus, cellular proliferation. Due to its central role in cancer cell pathology, malignant cells often overexpress TFR1 and this increased expression can be associated with poor prognosis in different types of cancer. The elevated levels of TfR1 expression on malignant cells, together with its extracellular accessibility, ability to internalize, and central role in cancer cell pathology make this receptor an attractive target for antibody-mediated therapy.
  • the antibodies or antigen-binding fragments thereof described herein cannot block the binding between TFR1 and TF. In some embodiments, the antibodies or antigen-binding fragments thereof described herein can block the binding between TFR1 and TF. In some embodiments, the antibodies or antigen-binding fragments thereof described herein can be conjugated to anti-cancer agents that are internalized by receptor-mediated endocytosis. In some embodiments, the antibodies or antigen-binding fragments thereof described herein can disrupt the function of the receptor. In some embodiments, the antibodies or antigen-binding fragments thereof described herein cannot induce Fc effector functions, therefore preventing or ameliorating their negative effects to normal cells.
  • the disclosure provides antibodies or antigen-binding fragments thereof comprising a human Fc domain, which induce Fc-dependent effector functions by at least or about at least or about 1 fold, at least or about 2 folds, at least or about 3 folds, at least or about 4 folds, at least or about 5 folds, at least or about 6 folds, at least or about 7 folds, at least or about 8 folds, at least or about 9 folds, at least or about 10 folds, at least or about 20 folds, at least or about 30 folds, at least or about 40 folds, at least or about 50 folds, or at least or about 100 folds as compared when no antibodies or antigen-binding fragments thereof as described herein are present.
  • the disclosure provides antibodies or antigen-binding fragments thereof comprising a human Fc domain, which induce host immune response by at least or about at least or about 1 fold, at least or about 2 folds, at least or about 3 folds, at least or about 4 folds, at least or about 5 folds, at least or about 6 folds, at least or about 7 folds, at least or about 8 folds, at least or about 9 folds, at least or about 10 folds, at least or about 20 folds, at least or about 30 folds, at least or about 40 folds, at least or about 50 folds, or at least or about 100 folds as compared when no antibodies or antigen-binding fragments thereof as described herein are present.
  • the disclosure provides antibodies or antigen-binding fragments thereof that can internalize into human brain cells (e.g., cortical microvascular endothelial cells) that the endocytosis rate is at least 50%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.
  • human brain cells e.g., cortical microvascular endothelial cells
  • the endocytosis rate of the antibodies or antigen-binding fragments thereof described herein is at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 50-fold, 100-fold, 500-fold, or 1000-fold as compared to that of an isotype control antibody.
  • an antibody or antigen-binding fragment thereof comprising a single heavy chain. In some embodiments, provided herein is an antibody or antigen-binding fragment thereof comprising a pair of heavy chains. In some embodiments, the heavy chain pair is linked by disulfide bonds. In some embodiments, the heavy chain pair comprises knob-in-hole modifications. In some embodiments, the heavy chain comprises a human IgG Fc domain. In some embodiments, the antibody or antigen-binding fragment thereof comprises in each heavy chain at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 VHH domains. In some embodiments, the VHH domains in each heavy chain specifically bind to the same epitope. In some embodiments, the VHH domains in each heavy chain specifically bind to different epitopes. In some embodiments, the VHH domains in each heavy chain bind to at least 1, 2, 3, 4, or 5 different epitopes.
  • the antibody or antigen-binding fragment thereof is a bi-specific antibody, or tri-specific antibody. In some embodiments, the antibody or antigen-binding fragment thereof can specifically bind to at least 4, 5, or 6 antigens.
  • the antibody specifically binds to TFR1 with a dissociation rate (koff) of less than 0.1 s -1 , less than 0.01 s -1 , less than 0.001 s -1 , less than 0.0001 s -1 , or less than 0.00001 s -1 .
  • the dissociation rate (koff) is greater than 0.01 s -1 , greater than 0.001 s -1 , greater than 0.0001 s -1 , greater than 0.00001 s -1 , or greater than 0.000001 s -1 .
  • kinetic association rates (kon) is greater than 1 ⁇ 10 2 /Ms, greater than 1 ⁇ 10 3 /Ms, greater than 1 ⁇ 10 4 /Ms, greater than 1 ⁇ 10 5 /Ms, or greater than 1 ⁇ 10 6 /Ms. In some embodiments, kinetic association rates (kon) is less than 1 ⁇ 10 5 /Ms, less than 1 ⁇ 10 6 /Ms, or less than 1 ⁇ 10 7 /Ms.
  • KD is less than 1 ⁇ 10 -6 M, less than 1 ⁇ 10 -7 M, less than 1 ⁇ 10 -8 M, less than 1 ⁇ 10 -9 M, or less than 1 ⁇ 10 -10 M. In some embodiments, the KD is less than 50 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM.
  • KD is greater than 1 x 10 -7 M, greater than 1 x 10 -8 M, greater than 1 x 10 -9 M, greater than 1 x 10 -10 M, greater than 1 x 10 -11 M, or greater than 1 x 10 -12 M.
  • the antibody binds to human TFR1, monkey TFR1, mouse TFR1, or chimeric TFR1. In some embodiments, the antibody does not bind to human TFR1, monkey TFR1, mouse TFR1, or chimeric TFR1.
  • thermal stabilities are determined.
  • the antibodies or antigen-binding fragments as described herein can have a Tm (melting temperature) greater than 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 °C.
  • Tm is less than 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 °C.
  • the antibodies or antigen-binding fragments as described herein can have a Tagg (aggregation temperature, e.g., Tagg at 266 nm (Tagg266) or Tagg at 473 nm (Tagg473) ) great than 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 °C.
  • Tagg aggregation temperature, e.g., Tagg at 266 nm (Tagg266) or Tagg at 473 nm (Tagg473)
  • Tagg is less than 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95 °C.
  • the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4.
  • the antibodies or antigen binding fragments thereof have a functional Fc region.
  • the antibodies or antigen binding fragments thereof comprise a human IgG1 Fc region.
  • the human IgG1 Fc region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to SEQ ID NO: 34.
  • the antibodies or antigen binding fragments do not have an Fc region.
  • the antibody (or antigen-binding fragment thereof) is a polypeptide comprising one or more VHH domains that are interconnected by linker peptides.
  • the antibody comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 VHH domain.
  • the VHH domains specifically bind to the same epitope.
  • the VHH domains bind to different epitopes.
  • the VHH domains bind to at least 1, 2, 3, 4, or 5 different epitopes.
  • the antibodies or antigen binding fragments thereof do not have a functional Fc region.
  • the Fc region has LALA mutations (L234A and L235A mutations in EU numbering) , or LALA-PG mutations (L234A, L235A, P329G mutations in EU numbering) .
  • the Fc region has a mutation at position 297 (e.g., N297A) according to EU numbering.
  • the mutated human IgG1 Fc region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%identical to SEQ ID NO: 35.
  • concentration of the antibody or antigen binding fragment thereof described herein in brain can be greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80%of its concentration immediately (e.g., 0.5 hour) after administration.
  • concentration of the antibody or antigen binding fragment thereof described herein in brain can be at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 1000-fold, 2000-fold, 5000-fold, or 10000-fold of the concentration of a control antibody (e.g., hIgG1 or JR141-N) , or the concentration in serum of the subject.
  • a control antibody e.g., hIgG1 or JR141-N
  • Variants of the antibodies or antigen-binding fragments described herein can be prepared by introducing appropriate nucleotide changes into the DNA encoding a human, humanized, or chimeric antibody, or antigen-binding fragment thereof described herein, or by peptide synthesis.
  • Such variants include, for example, deletions, insertions, or substitutions of residues within the amino acids sequences that make-up the antigen-binding site of the antibody or an antigen-binding domain.
  • some antibodies or antigen-binding fragments will have increased affinity for the target protein, e.g., TFR1.
  • any combination of deletions, insertions, and/or combinations can be made to arrive at an antibody or antigen-binding fragment thereof that has increased binding affinity for the target.
  • the amino acid changes introduced into the antibody or antigen-binding fragment can also alter or introduce new post-translational modifications into the antibody or antigen-binding fragment, such as changing (e.g., increasing or decreasing) the number of glycosylation sites, changing the type of glycosylation site (e.g., changing the amino acid sequence such that a different sugar is attached by enzymes present in a cell) , or introducing new glycosylation sites.
  • the heavy-chain antibody or antigen-binding fragment thereof described herein is obtained by immunizing any of the genetically modified animals (e.g., mice with complete human heavy chain variable domain substitution in situ, combined with a modified constant region) described e.g., in PCT/CN2022/119188.
  • the genetically modified animals e.g., mice with complete human heavy chain variable domain substitution in situ, combined with a modified constant region
  • Humanized antibodies include antibodies having variable and constant regions derived from (or having the same amino acid sequence as those derived from) human germline immunoglobulin sequences of human immunoglobulin scaffold sequences. Humanized antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo) . Accordingly, “humanized” antibodies are chimeric antibodies wherein sequences from a non-human species are substituted by the corresponding human sequences.
  • amino acid sequence variants of the human, humanized, or chimeric anti-TFR1 antibody will contain an amino acid sequence having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%percent identity with a sequence present in the VHH domain of the original antibody.
  • Identity or homology with respect to an original sequence is usually the percentage of amino acid residues present within the candidate sequence that are identical with a sequence present within the human, humanized, or chimeric anti-TFR1 antibody or fragment, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
  • a cysteine residue can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated may have any increased half-life in vitro and/or in vivo.
  • Homodimeric antibodies with increased half-life in vitro and/or in vivo can also be prepared using heterobifunctional cross-linkers as described, for example, in Wolff et al. Wolff et al. ( "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. " Cancer research 53.11 (1993) : 2560-2565) .
  • an antibody can be engineered which has dual Fc regions.
  • a covalent modification can be made to the anti-TFR1 antibody or antigen-binding fragment thereof.
  • These covalent modifications can be made by chemical or enzymatic synthesis, or by enzymatic or chemical cleavage.
  • Other types of covalent modifications of the antibody or antibody fragment are introduced into the molecule by reacting targeted amino acid residues of the antibody or fragment with an organic derivatization agent that is capable of reacting with selected side chains or the N-or C-terminal residues.
  • antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
  • the amount of fucose in such antibody composition may be from 1%to 80%, from 1%to 65%, from 5%to 65%or from 20%to 40%.
  • the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e.g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
  • Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues; or position 314 in Kabat numbering) ; however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function.
  • the Fc region of the antibody can be further engineered to replace the Asparagine at position 297 with Alanine (N297A) .
  • the present disclosure also provides recombinant vectors (e.g., an expression vectors) that include an isolated polynucleotide disclosed herein (e.g., a polynucleotide that encodes a polypeptide disclosed herein) , host cells into which are introduced the recombinant vectors (i.e., such that the host cells contain the polynucleotide and/or a vector comprising the polynucleotide) , and the production of recombinant antibody polypeptides or fragments thereof by recombinant techniques.
  • recombinant vectors e.g., an expression vectors
  • an isolated polynucleotide disclosed herein e.g., a polynucleotide that encodes a polypeptide disclosed herein
  • host cells into which are introduced the recombinant vectors (i.e., such that the host cells contain the polynucleotide and/or a vector comprising the polynucleo
  • a “vector” is any construct capable of delivering one or more polynucleotide (s) of interest to a host cell when the vector is introduced to the host cell.
  • An “expression vector” is capable of delivering and expressing the one or more polynucleotide (s) of interest as an encoded polypeptide in a host cell into which the expression vector has been introduced.
  • the polynucleotide of interest is positioned for expression in the vector by being operably linked with regulatory elements such as a promoter, enhancer, and/or a poly-Atail, either within the vector or in the genome of the host cell at or near or flanking the integration site of the polynucleotide of interest such that the polynucleotide of interest will be translated in the host cell introduced with the expression vector.
  • regulatory elements such as a promoter, enhancer, and/or a poly-Atail
  • a vector can be introduced into the host cell by methods known in the art, e.g., electroporation, chemical transfection (e.g., DEAE-dextran) , transformation, transfection, and infection and/or transduction (e.g., with recombinant virus) .
  • vectors include viral vectors (which can be used to generate recombinant virus) , naked DNA or RNA, plasmids, cosmids, phage vectors, and DNA or RNA expression vectors associated with cationic condensing agents.
  • a polynucleotide disclosed herein e.g., a polynucleotide that encodes a polypeptide disclosed herein
  • a viral expression system e.g., vaccinia or other pox virus, retrovirus, or adenovirus
  • vaccinia or other pox virus, retrovirus, or adenovirus may involve the use of a non-pathogenic (defective) , replication competent virus, or may use a replication defective virus.
  • viral propagation generally will occur only in complementing virus packaging cells. Suitable systems are disclosed, for example, in Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA 86: 317-321; Flexner et al., 1989, Ann. N. Y.
  • the DNA insert comprising an antibody-encoding or polypeptide-encoding polynucleotide disclosed herein can be operatively linked to an appropriate promoter (e.g., a heterologous promoter) , such as the phage lambda PL promoter, the E. coli lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters are known to the skilled artisan.
  • the promoter is a cytomegalovirus (CMV) promoter.
  • CMV cytomegalovirus
  • the expression constructs can further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation.
  • the coding portion of the mature transcripts expressed by the constructs may include a translation initiating at the beginning and a termination codon (UAA, UGA, or UAG) appropriately positioned at the end of the polypeptide to be translated.
  • the expression vectors can include at least one selectable marker.
  • markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in E. coli and other bacteria.
  • Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces, and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, Bowes melanoma, and HK 293 cells; and plant cells. Appropriate culture mediums and conditions for the host cells described herein are known in the art.
  • Non-limiting vectors for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.
  • Non-limiting eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.
  • Non-limiting bacterial promoters suitable for use include the E. coli lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters and the trp promoter.
  • Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV) , and metallothionein promoters, such as the mouse metallothionein-I promoter.
  • yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used.
  • Introduction of the construct into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods.
  • Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) , which is incorporated herein by reference in its entirety.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type.
  • enhancers include the SV40 enhancer, which is located on the late side of the replication origin at base pairs 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • secretion signals may be incorporated into the expressed polypeptide.
  • the signals may be endogenous to the polypeptide or they may be heterologous signals.
  • the polypeptide (e.g., antibody) can be expressed in a modified form, such as a fusion protein (e.g., a GST-fusion) or with a histidine-tag, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to the polypeptide to facilitate purification. Such regions can be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art.
  • the disclosure also provides a nucleic acid sequence that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%identical to any nucleotide sequence as described herein, and an amino acid sequence that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%identical to any amino acid sequence as described herein.
  • the disclosure relates to nucleotide sequences encoding any peptides that are described herein, or any amino acid sequences that are encoded by any nucleotide sequences as described herein.
  • the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides.
  • the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 amino acid residues.
  • the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any one of the sequences as described herein.
  • the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any one of the sequences as described herein.
  • the antibody or antigen-binding fragment thereof is expressed in yeast, insect cells, or mammalian cells (e.g., CHO cells) .
  • the disclosure provides methods for treating a brain disease (e.g., brain cancer, dementia, or Alzheimer’s disease) in a subject, methods of identifying a subject having a brain disease (e.g., brain cancer, dementia, or Alzheimer’s disease) , methods of reducing the risk of developing a brain disease, or methods of reducing the risk of developing additional symptoms in a subject.
  • the treatment can halt, slow, retard, or inhibit progression of a brain disease (e.g., brain cancer, dementia, or Alzheimer’s disease) .
  • the treatment can result in the reduction of in the number, severity, and/or duration of one or more symptoms of a brain disease (e.g., brain cancer, dementia, or Alzheimer’s disease) in a subject.
  • the disclosure features methods that include administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof disclosed herein to a subject in need thereof (e.g., a subject having, or identified or diagnosed as having, a brain disease) .
  • the disclosure features methods that carry a therapeutic agent to cross the blood brain barrier.
  • the antibodies or antigen-binding fragments thereof as described herein are linked to the therapeutic agent.
  • the therapeutic agent is an antibody, an antigen binding fragment thereof, a small molecule, or an antibody-drug conjugate.
  • compositions and methods disclosed herein can be used for treatment of patients at risk for a brain disease (e.g., brain cancer, dementia, or Alzheimer’s disease) .
  • a brain disease e.g., brain cancer, dementia, or Alzheimer’s disease
  • Patients with a brain disease can be identified with various methods known in the art.
  • the brain disease is a brain cancer.
  • the disclosure is related to methods of decreasing the rate of tumor growth, including contacting a tumor cell with an effective amount of a composition including the antibody or antigen-binding fragment thereof, or the antibody-drug conjugate described herein. In one aspect, the disclosure is related to methods of killing a tumor cell, including contacting a tumor cell with an effective amount of a composition including the antibody or antigen-binding fragment thereof, or the antibody-drug conjugate described herein.
  • an “effective amount” is meant an amount or dosage sufficient to effect beneficial or desired results including halting, slowing, retarding, or inhibiting progression of a disease, e.g., a cancer.
  • An effective amount will vary depending upon, e.g., an age and a body weight of a subject to which the antibody, antigen binding fragment, antibody-encoding polynucleotide, vector comprising the polynucleotide, and/or compositions thereof is to be administered, a severity of symptoms and a route of administration, and thus administration can be determined on an individual basis.
  • an effective amount can be administered in one or more administrations.
  • an effective amount of an antibody or an antigen binding fragment thereof is an amount sufficient to ameliorate, stop, stabilize, reverse, inhibit, slow and/or delay progression of a disease in a patient.
  • an effective amount of an antibody or antigen binding fragment may vary, depending on, inter alia, patient history as well as other factors such as the type (and/or dosage) of antibody used.
  • Effective amounts and schedules for administering the antibodies, antibody-encoding polynucleotides, and/or compositions disclosed herein may be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dosage that must be administered will vary depending on, for example, the mammal that will receive the antibodies, antibody-encoding polynucleotides, and/or compositions disclosed herein, the route of administration, the particular type of antibodies, antibody-encoding polynucleotides, antigen binding fragments, and/or compositions disclosed herein used and other drugs being administered to the mammal.
  • a typical daily dosage of an effective amount of an antibody is 0.01 mg/kg to 100 mg/kg.
  • the dosage can be less than 100 mg/kg, 10 mg/kg, 9 mg/kg, 8 mg/kg, 7 mg/kg, 6 mg/kg, 5 mg/kg, 4 mg/kg, 3 mg/kg, 2 mg/kg, 1 mg/kg, 0.5 mg/kg, or 0.1 mg/kg.
  • the dosage can be greater than 10 mg/kg, 9 mg/kg, 8 mg/kg, 7 mg/kg, 6 mg/kg, 5 mg/kg, 4 mg/kg, 3 mg/kg, 2 mg/kg, 1 mg/kg, 0.5 mg/kg, 0.1 mg/kg, 0.05 mg/kg, or 0.01 mg/kg.
  • the dosage is about 10 mg/kg, 9 mg/kg, 8 mg/kg, 7 mg/kg, 6 mg/kg, 5 mg/kg, 4 mg/kg, 3 mg/kg, 2 mg/kg, 1 mg/kg, 0.9 mg/kg, 0.8 mg/kg, 0.7 mg/kg, 0.6 mg/kg, 0.5 mg/kg, 0.4 mg/kg, 0.3 mg/kg, 0.2 mg/kg, or 0.1 mg/kg.
  • the at least one antibody, antigen-binding fragment thereof, or pharmaceutical composition e.g., any of the antibodies, antigen-binding fragments, or pharmaceutical compositions described herein
  • at least one additional therapeutic agent can be administered to the subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day, or three times a day) .
  • at least two different antibodies and/or antigen-binding fragments are administered in the same composition (e.g., a liquid composition) .
  • At least one antibody or antigen-binding fragment and at least one additional therapeutic agent are administered in the same composition (e.g., a liquid composition) .
  • the at least one antibody or antigen-binding fragment and the at least one additional therapeutic agent are administered in two different compositions (e.g., a liquid composition containing at least one antibody or antigen-binding fragment and a solid oral composition containing at least one additional therapeutic agent) .
  • the at least one additional therapeutic agent is administered as a pill, tablet, or capsule.
  • the at least one additional therapeutic agent is administered in a sustained-release oral formulation.
  • the one or more additional therapeutic agents can be administered to the subject prior to, or after administering the at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) .
  • the one or more additional therapeutic agents and the at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition are administered to the subject such that there is an overlap in the bioactive period of the one or more additional therapeutic agents and the at least one antibody or antigen-binding fragment (e.g., any of the antibodies or antigen-binding fragments described herein) in the subject.
  • the subject can be administered the at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen- binding antibody fragments, or pharmaceutical compositions described herein) over an extended period of time (e.g., over a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years) .
  • a skilled medical professional may determine the length of the treatment period using any of the methods described herein for diagnosing or following the effectiveness of treatment (e.g., the observation of at least one symptom of the disease) .
  • a skilled medical professional can also change the identity and number (e.g., increase or decrease) of antibodies or antigen-binding antibody fragments (and/or one or more additional therapeutic agents) administered to the subject and can also adjust (e.g., increase or decrease) the dosage or frequency of administration of at least one antibody or antigen-binding antibody fragment (and/or one or more additional therapeutic agents) to the subject based on an assessment of the effectiveness of the treatment (e.g., using any of the methods described herein and known in the art) .
  • one or more additional therapeutic agents can be administered to the subject.
  • the additional therapeutic agent can comprise one or more inhibitors selected from the group consisting of an inhibitor of B-Raf, an EGFR inhibitor, an inhibitor of a MEK, an inhibitor of ERK, an inhibitor of K-Ras, an inhibitor of c-Met, an inhibitor of anaplastic lymphoma kinase (ALK) , an inhibitor of a phosphatidylinositol 3-kinase (PI3K) , an inhibitor of an Akt, an inhibitor of mTOR, a dual PI3K/mTOR inhibitor, an inhibitor of Bruton's tyrosine kinase (BTK) , and an inhibitor of Isocitrate dehydrogenase 1 (IDH1) and/or Isocitrate dehydrogenase 2 (IDH2) .
  • Isocitrate dehydrogenase 1 IDH1
  • Isocitrate dehydrogenase 2 IDH2
  • the additional therapeutic agent can comprise one or more inhibitors selected from the group consisting of an inhibitor of HER3, an inhibitor of LSD1, an inhibitor of MDM2, an inhibitor of BCL2, an inhibitor of CHK1, an inhibitor of activated hedgehog signaling pathway, and an agent that selectively degrades the estrogen receptor.
  • the additional therapeutic agent can comprise one or more therapeutic agents selected from the group consisting of Trabectedin, nab-paclitaxel, Trebananib, Pazopanib, Cediranib, Palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib, Reolysin, Alimta, Zykadia, Sutent, temsirolimus, axitinib, everolimus, sorafenib, Votrient, Pazopanib, IMA-901, AGS-003, cabozantinib, Vinflunine, an Hsp90 inhibitor, Ad-GM-CSF, Temazolomide, IL-2, IFNa, vinblastine, Thalomid, dacarbazine, cyclophosphamide, lenalidomide, azacytidine, lenalidomide, bortezomid, amrubicine, carfilzomib, prala
  • therapeutic agents
  • the additional therapeutic agent can comprise one or more therapeutic agents selected from the group consisting of an adjuvant, a TLR agonist, tumor necrosis factor (TNF) alpha, IL-1, HMGB1, an IL-10 antagonist, an IL-4 antagonist, an IL-13 antagonist, an IL-17 antagonist, an HVEM antagonist, an ICOS agonist, a treatment targeting CX3CL1, a treatment targeting CXCL9, a treatment targeting CXCL10, a treatment targeting CCL5, an LFA-1 agonist, an ICAM1 agonist, and a Selectin agonist.
  • TNF tumor necrosis factor
  • carboplatin, nab-paclitaxel, paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI are administered to the subject.
  • the additional therapeutic agent is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, an anti-4-1BB antibody, an anti-CTLA-4 antibody, an anti-CD40 antibody, an anti-OX40 antibody, or an anti-GITR antibody.
  • compositions that contain at least one (e.g., one, two, three, or four) of the antibodies or antigen-binding fragments described herein. Two or more (e.g., two, three, or four) of any of the antibodies or antigen-binding fragments described herein can be present in a pharmaceutical composition in any combination.
  • the pharmaceutical compositions may be formulated in any manner known in the art.
  • compositions are formulated to be compatible with their intended route of administration (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) .
  • the compositions can include a sterile diluent (e.g., sterile water or saline) , a fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvents, antibacterial or antifungal agents, such as benzyl alcohol or methyl parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like, antioxidants, such as ascorbic acid or sodium bisulfite, chelating agents, such as ethylenediaminetetraacetic acid, buffers, such as acetates, citrates, or phosphates, and isotonic agents, such as sugars (e.g., dextrose) , polyalcohols (e.g., mannitol or
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers (see, e.g., U.S. Patent No. 4,522,811) .
  • Preparations of the compositions can be formulated and enclosed in ampules, disposable syringes, or multiple dose vials. Where required (as in, for example, injectable formulations) , proper fluidity can be maintained by, for example, the use of a coating, such as lecithin, or a surfactant.
  • Absorption of the antibody or antigen-binding fragment thereof can be prolonged by including an agent that delays absorption (e.g., aluminum monostearate and gelatin) .
  • controlled release can be achieved by implants and microencapsulated delivery systems, which can include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc. ) .
  • biodegradable, biocompatible polymers e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.
  • compositions containing one or more of any of the antibodies or antigen-binding fragments described herein can be formulated for parenteral (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration in dosage unit form (i.e., physically discrete units containing a predetermined quantity of active compound for ease of administration and uniformity of dosage) .
  • parenteral e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal
  • dosage unit form i.e., physically discrete units containing a predetermined quantity of active compound for ease of administration and uniformity of dosage
  • Toxicity and therapeutic efficacy of compositions can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (e.g., monkeys) .
  • Agents that exhibit high therapeutic indices are preferred. Where an agent exhibits an undesirable side effect, care should be taken to minimize potential damage (i.e., reduce unwanted side effects) .
  • Toxicity and therapeutic efficacy can be determined by other standard pharmaceutical procedures.
  • a therapeutically effective amount of the one or more (e.g., one, two, three, or four) antibodies or antigen-binding fragments thereof (e.g., any of the antibodies or antibody fragments described herein) will be an amount that treats the disease in a subject in a subject, or a subject identified as being at risk of developing the disease, decreases the severity, frequency, and/or duration of one or more symptoms of a disease in a subject (e.g., a human) .
  • any of the antibodies or antigen-binding fragments described herein can be determined by a health care professional or veterinary professional using methods known in the art, as well as by the observation of one or more symptoms of disease in a subject (e.g., a human) . Certain factors may influence the dosage and timing required to effectively treat a subject (e.g., the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and the presence of other diseases) .
  • Exemplary doses include milligram or microgram amounts of any of the antibodies or antigen-binding fragments described herein per kilogram of the subject’s weight (e.g., about 1 ⁇ g/kg to about 500 mg/kg; about 100 ⁇ g/kg to about 500 mg/kg; about 100 ⁇ g/kg to about 50 mg/kg; about 10 ⁇ g/kg to about 5 mg/kg; about 10 ⁇ g/kg to about 0.5 mg/kg; or about 1 ⁇ g/kg to about 50 ⁇ g/kg) . While these doses cover a broad range, one of ordinary skill in the art will understand that therapeutic agents, including antibodies and antigen-binding fragments thereof, vary in their potency, and effective amounts can be determined by methods known in the art.
  • relatively low doses are administered at first, and the attending health care professional or veterinary professional (in the case of therapeutic application) or a researcher (when still working at the development stage) can subsequently and gradually increase the dose until an appropriate response is obtained.
  • the specific dose level for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, and the half-life of the antibody or antibody fragment in vivo.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • disclosure also provides methods of manufacturing the antibodies or antigen binding fragments thereof for various uses as described herein.
  • RenNano TM mice Biocytogen, complete human heavy chain variable domain substitution in situ, combined with a modified constant region. The mice are described e.g., in PCT/CN2022/119188, which is incorporated herein by reference in its entirety) were immunized with His-tagged human TFR1 (transferrin receptor 1) protein (hTFR1-His, ACROBiosystems, Cat#: CD1-H5243) to obtain anti-TFR1 antibodies.
  • retro-orbital blood was collected as a negative control.
  • Freund’s complete adjuvant (CFA) was used for the first immunization
  • Freund’s incomplete adjuvant (IFA) was used for the second and third immunizations. A total of three immunizations (bi-weekly) were performed.
  • One week after the third immunization retro-orbital blood was collected, and the antibody titer of serum was detected by FACS.
  • TFR1 protein was injected by intraperitoneal injection, and the CHO-Scells expressing human TFR1 antigen was injected through the tail vein.
  • Antigen-specific immune cells were isolated from the immunized mice to further obtain anti-TFR1 antibodies or to obtain the heavy chain variable region sequences of the anti-TFR1 antibodies.
  • single cell technology e.g., using Optofluidic System, Berkeley Lights Inc.
  • Reverse transcription and PCR sequencing were used to obtain antibody variable region sequences.
  • the obtained variable region sequences were used for antibody expression to verify the binding activity to TFR1 using FACS. Because the lack of the CH1 domain, the heavy chain variable region (VH) of the obtained antibodies is also referred to as a heavy chain single variable domain (VHH) .
  • VHH sequences were respectively connected to a human IgG1 constant region (e.g., the hinge region, CH2 domain and CH3 domain) .
  • exemplary antibodies obtained by this method included: 23B8, 24A1, 24C9 and 24G5.
  • the heavy chain CDR1-3 sequences are shown in FIG. 1 and FIG. 2.
  • the VHH region sequences of 23B8, 24A1, 24C9 and 24G5 are shown in FIG. 3.
  • the constant region of the antibodies can be further engineered to replace the Asparagine at position 297 with Alanine (N297A) .
  • N297A mutation is introduced into the constant region of 24G5
  • the resulting antibody is named as 24G5-N.
  • one-armed antibodies 23B8-mono, 24A1-mono, 24C9-mono and 24G5-mono were constructed, these antibodies have an anti-TFR1 arm comprising a VHH region, and a heavy chain fragment comprising CH2 and CH3 domains of IgG1 with N297A mutation.
  • CHO-S-hTFR1 cells or CHO-S-fasTFR1 cells were transferred to a 96-well plate at a density of 10 5 cells/well respectively.
  • Serially diluted sample anti-TFR1 antibodies were added to the 96-well plate, and incubated at 4°C for 30 minutes.
  • PBS was used as a negative control (NC) .
  • the cells were incubated with the secondary antibody anti-hIgG-Fc-Alex Flour TM 647 (Jackson ImmunoResearch Laboratories, Cat#: 109-606-170) at 4°C in the dark for 15 minutes before flow cytometry analysis.
  • CHO-S-hTFR1 cells or CHO-S-fasTFR1 cells were obtained by transfecting CHO-Scells with vectors expressing human TFR1 (hTFR1, SEQ ID NO: 29) or Macaca fascicularis (crab-eating macaque) TFR1 amino acid sequence (fasTFR1, SEQ ID NO: 30) , respectively.
  • the test results are shown in the table below.
  • JR141 a humanized IgG1 antibody targeting human TFR1 conjugated to human iduronate-2-sulfatase, was first approved in March 2021 in Japan for the intravenous treatment of mucopolysaccharidosis type II.
  • the VH and VL sequences of JR141 are set forth in SEQ ID NO: 31 and SEQ ID NO: 32, respectively.
  • positive control JR141-N
  • the VH and VL of JR141 were connected to a human IgG1 constant region with N297A mutation.
  • the binding affinity of the anti-TFR1 antibodies to His-tagged TFR1 protein of human (hTFR1-His, ACROBiosystems, Cat#: CD1-H5243) or monkey (fasTFR1-His, ACROBiosystems, Cat#: TFR-C524a) were verified using surface plasmon resonance (SPR) on Biacore TM (Biacore, Inc., Piscataway N. J. ) 8K biosensor equipped with pre-immobilized Protein A sensor chips.
  • SPR surface plasmon resonance
  • Purified anti-TFR1 antibodies was captured on the Protein A chip (Series S Sensor Chip Protein A) for the detection.
  • Purified anti-TFR1 antibodies (1 ⁇ g/mL) was loaded at 10 ⁇ L/min to bind to hTFR1-His and fasTFR1-His (200 nM) .
  • the flow rate was 30 ⁇ L/min.
  • the binding and dissociation time were set to 180 seconds and 600 seconds, respectively.
  • the chip was regenerated after the last injection of each titration with a glycine solution (pH 2.0) at 30 ⁇ L/min for 30 seconds.
  • HBS-EP+ buffer 10 mM 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid (HEPES) , 150 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA) and 0.05%P20, pH7.4) diluted from HBS-EP+ buffer (10 ⁇ ) was used as the running buffer throughout the experiment.
  • HBS-EP+ buffer 10 mM 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid (HEPES) , 150 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA) and 0.05%P20, pH7.4
  • HIS1K Anti-Penta-HIS
  • Analyte 1 was injected at a flow rate of 30 ⁇ L/min to bind the ligand.
  • Another antibody was injected under the same conditions to determine whether the binding of different antibodies interfered with each other. The binding time was 300 seconds for each antibody.
  • the binding value of each antibody was obtained using Data Analysis HT 12.0. To quantify the interference of one antibody binding to another, a binding ratio was calculated to compare each pair of antibodies. The binding ratio is defined as the binding value of the second antibody (analyte 2) , divided by the binding value of the first antibody (analyte 1) . The binding ratio of each antibody pair is summarized in the matrix table below. Specifically, the binding ratio was between 0.0 to 0.5, if analyte 1 exhibited a blocking effect to analyte 2; the binding ratio was between 0.5-1.1, if analyte 1 did not exhibit a blocking effect to analyte 2. In general, antibody pairs that interfere with each other have the same or overlapping epitopes.
  • the epitope binding assay results indicate that 24A1 and 24G5 can recognize the same epitope, and 23B8, 24C9 and JR141-N can recognize different epitopes.
  • Anti-TFR1 antibodies together with the pHAb-Goat anti-human IgG secondary antibody were added to human cortical microvascular endothelial cells (hCMEC/D3 cells) , and incubated for 3 hours. After incubation, the cells were centrifuged and washed with FACS buffer. Mean fluorescence intensity (MFI) was measured using a flow cytometer. Endocytosis rates of antibodies were calculated.
  • Human IgG1 protein (CrownBio, Cat#: C0001) was used as an isotype control (ISO) . The results are shown in the following table, indicating that all four antibodies exhibited good endocytosis activity in human cortical microvascular endothelial cells.
  • the Agilent 1290 chromatograph system (connected with XBridge TM Protein BEH SEC column ( Waters Corporation) ) was used.
  • the antibody samples were diluted to 1 mg/mL with purified water.
  • the following parameters were used: mobile phase: 25 mM phosphate buffer (PB) (pH 6.8) + 0.3 M NaCl; flow rate: 1.8 mL/min; column temperature: 25 °C; detection wavelength: 280 nm; injection volume: 10 ⁇ L; sample tray temperature: 6 °C; and running time: 7 minutes.
  • PB phosphate buffer
  • flow rate 1.8 mL/min
  • column temperature 25 °C
  • detection wavelength 280 nm
  • injection volume 10 ⁇ L
  • sample tray temperature 6 °C
  • running time 7 minutes.
  • mobile phase A 0.9 M ammonium sulfate, 0.1 M PB, 10%acetonitrile pH 6.5
  • mobile phase B 0.1 M PB, 10%acetonitrile pH 6.5
  • flow rate 0.8 mL/min
  • gradient 0 min 100%A, 2 min 100%A, 32 min 100%B, 34 min 100%B, 35 min 100%A, and 45 min 100%A
  • column temperature 30 °C
  • detection wavelength 280 nm
  • injection volume 10 ⁇ g
  • sample tray temperature about 6 °C
  • running time 45 minutes.
  • the Maurice cIEF Method Development Kit (Protein Simple, Cat#: PS-MDK01-C) was used for sample preparation. Specifically, 40 ⁇ g protein sample was mixed with the following reagents in the kit: 1 ⁇ L Maurice cIEF pI Marker-4.05, 1 ⁇ L Maurice cIEF pI Marker-9.99, 35 ⁇ L 1%Methyl Cellulose Solution, 2 ⁇ L Maurice cIEF 500 mM Arginine, 4 ⁇ L Ampholytes (Pharmalyte pH ranges 3-10) , and water (added to make a final volume of 100 ⁇ L) .
  • Maurice cIEF Cartridges PS-MC02-C were used to generate imaging capillary isoelectric focusing spectra. The sample was focused for a total of 10 minutes. The analysis software installed on the instrument was used to analyze the absorbance of the 280 nm-focused protein.
  • the antibodies were diluted to 1 mg/mL using PBS buffer, and the following tests were performed: (1) detecting the specificity of the antibodies using the Cross-Interaction Chromatography (CIC) method (indicated as the retention time (CIC, min) ) ; (2) detecting the colloidal stabilities of the antibodies by the stand-up monolayer chromatography (SMAC) method (indicated as the retention time (SMAC, %/min) ) .
  • CIC Cross-Interaction Chromatography
  • SMAC stand-up monolayer chromatography
  • a CIC column was prepared by coupling human polyclonal IgGs (Sigma, Cat #: I4506) onto a HiTrap NHS-activated resin (GE Healthcare, Cat #: 17-0716-01) followed by passivation with ethanolamine according to published procedures.
  • the column was then connected to Agilent 1260 chromatograph system and run at 0.1 mL/min using 1 ⁇ PBS as the mobile phase until a flat baseline was reached. 10 ⁇ g of antibodies at 1 mg/mL in PBS were then injected. Peak retention times on the column were monitored at 280 nm; running time: 50 minutes.
  • Zenix column (4.6 mm ⁇ 30 cm, Sepax, Cat #: 213300-4630) was connected to the column compartment, and place the appropriate line in the mobile phase. Equilibrate column for 60 min at 0.350 mL/min flow rate with mobile phase buffer. Load antibodies into the injection sequence.
  • Mobile Phase A 150 mM Sodium Phosphate pH 7.0; flow rate: 0.35 mL/min; running time: 25 min; column temperature: 30°C; detection wavelength: 280 nm, 220 nm.
  • a humanized TFR1 mouse model (hTFR1 mice) was engineered to express a chimeric TFR1 protein (SEQ ID NO: 33) in which the extracellular region of mouse TFR1 protein was replaced with the corresponding human TFR1 extracellular region.
  • SEQ ID NO: 33 a chimeric TFR1 protein in which the extracellular region of mouse TFR1 protein was replaced with the corresponding human TFR1 extracellular region.
  • mice The concentrations of the anti-TFR1 antibodies were determined in hTFR1 mice. Specifically, the mice were placed into different groups (8 mice per group) , and administered with an approximately equal molar dosage of JR141-N (G2) , 23B8-N (G3) , 24A1-N (G4) , 24G5-N (G5) , or 24C9-N (G6) , by intravenous (i. v. ) injection.
  • the control group (G1) mice were administered with human IgG1 (hIgG1) . Details of the administration scheme are shown in the table below.
  • mice Blood and brain samples were collected 0.5, 6, 24, and 72 hours after the administration. Two mice were sampled at each time point, and the mice were anesthetized after retro-orbital blood was collected. To avoid interference from the residual blood in the brain, the mice were perfused by saline for 10 minutes at room temperature. Specifically, saline was perfused via systemic circulation from the left ventricle to the right ventricle. Brain samples were excised and divided into two hemibrains by the sagittal plane. The left hemibrain was subjected to quantification of the injected antibody, while the right hemibrain was fixed by formalin and embedded with paraffin for serial sections.
  • FIGS. 4A-4D show the antibody concentration in total brain protein (FIG. 4A) , the ratio of antibody concentration in brain total protein to serum antibody concentration (FIG.
  • hTFR1 mice were placed into five groups (3 mice per group) and administered with 18.4 mg/kg JR141-N (G2) , 10 mg/kg 23B8-N (G3) , 10 mg/kg 24A1-N (G4) , or 10 mg/kg 24G5-N (G5) by intravenous injection (1 administration in total) .
  • the control group (G1) mice were administered with hIgG1 (G1) .
  • brain samples were collected to determine the concentrations of the anti-TFR1 antibodies.
  • FIGS. 5A-5B show the antibody concentration test results in brain parenchyma and brain total protein, respectively.
  • hTFR1 mice were placed into seven groups (6 mice per group) and administered with JR141-N (G2-G4) or 24G5-N (G5-G7) ) by intravenous (i. v. ) injection.
  • the control group (G1) mice were administered with hIgG1. Details of the administration scheme are shown in the table below.
  • HBS-EP+ buffer 10 mM 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid (HEPES) , 150 mM NaCl, 3 mM EDTA and 0.05%Surfactant P20, pH 7.4
  • HBS-EP+ buffer 10 mM 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid (HEPES) , 150 mM NaCl, 3 mM EDTA and 0.05%Surfactant P20, pH 7.4
  • Each purified antibody (23B8-N, 24A1-N, 24C9-N, 24G5-N, 23B8-mono, 24A1-mono, 24C9-mono and 24G5-mono) was coupled with Dxd (Deruxtecan) through GGFG linker.
  • ADC is added directly after the antibody name.
  • 24G5-N is coupled to GGFG-Dxd, it is named as 24G5-ADC.
  • 24G5-mono is coupled to GGFG-Dxd, it is named as 24G5-mono-ADC.
  • HIC-HPLC Reversed Phase High Performance Liquid Chromatography
  • hTFR1 mice were placed into different groups (6 mice per group) and administered with 10 mg/kg bivalent anti-TFR1 ADCs (24G5-ADC, 23B8-ADC, 24A1-ADC, 24C9-ADC) or the same molar dose 8.34 mg/kg one-armed monovalent anti-TFR1 ADCs (23B8-mono-ADC, 24A1-mono-ADC, 24C9-mono-ADC, or 24G5-mono-ADC) by intravenous (i. v. ) injection (1 administration in total) . 0.5 hour, 18 hours and 72 hours after the administration, blood and brain samples were collected using the methods described in Example 7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne des anticorps anti-TFR1 (récepteur 1 de la transferrine), des fragments de liaison à l'antigène et leurs utilisations.
PCT/CN2023/135130 2022-12-02 2023-11-29 Anticorps anti-tfr1 et leurs utilisations Ceased WO2024114687A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202380082014.XA CN120282983A (zh) 2022-12-02 2023-11-29 抗tfr1抗体及其应用
AU2023404617A AU2023404617A1 (en) 2022-12-02 2023-11-29 Anti-tfr1 antibodies and uses thereof
JP2025531723A JP2025539455A (ja) 2022-12-02 2023-11-29 抗ｔｆｒ１抗体及びその使用
KR1020257018593A KR20250114322A (ko) 2022-12-02 2023-11-29 항-tfr1 항체 및 이의 용도
EP23896831.7A EP4626923A1 (fr) 2022-12-02 2023-11-29 Anticorps anti-tfr1 et leurs utilisations
IL320972A IL320972A (en) 2022-12-02 2025-05-18 Anti-TFR1 antibodies and their uses
MX2025006221A MX2025006221A (es) 2022-12-02 2025-05-28 Anticuerpos anti-tfr1 y usos de los mismos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/136246 2022-12-02
CN2022136246 2022-12-02

Publications (1)

Publication Number Publication Date
WO2024114687A1 true WO2024114687A1 (fr) 2024-06-06

Family

ID=91323009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/135130 Ceased WO2024114687A1 (fr) 2022-12-02 2023-11-29 Anticorps anti-tfr1 et leurs utilisations

Country Status (9)

Country Link
EP (1) EP4626923A1 (fr)
JP (1) JP2025539455A (fr)
KR (1) KR20250114322A (fr)
CN (1) CN120282983A (fr)
AU (1) AU2023404617A1 (fr)
IL (1) IL320972A (fr)
MX (1) MX2025006221A (fr)
TW (1) TW202440640A (fr)
WO (1) WO2024114687A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039908A1 (en) * 2004-06-07 2006-02-23 Mather Jennie P Transferrin receptor antibodies
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20130171061A1 (en) * 2011-12-29 2013-07-04 Ming-Hua Yang Anti-human transferrin receptor antibody and uses thereof
JP2014093958A (ja) * 2012-11-08 2014-05-22 Univ Of Miyazaki トランスフェリン受容体を特異的に認識できる抗体
WO2017013230A1 (fr) * 2015-07-22 2017-01-26 Inatherys Anticorps anti-tfr et leur utilisation dans le traitement des maladies prolifératives et inflammatoires
WO2020144233A1 (fr) * 2019-01-09 2020-07-16 Vect-Horus Molécules de liaison au récepteur de transferrine, leurs conjugués et leurs utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20060039908A1 (en) * 2004-06-07 2006-02-23 Mather Jennie P Transferrin receptor antibodies
US20130171061A1 (en) * 2011-12-29 2013-07-04 Ming-Hua Yang Anti-human transferrin receptor antibody and uses thereof
JP2014093958A (ja) * 2012-11-08 2014-05-22 Univ Of Miyazaki トランスフェリン受容体を特異的に認識できる抗体
WO2017013230A1 (fr) * 2015-07-22 2017-01-26 Inatherys Anticorps anti-tfr et leur utilisation dans le traitement des maladies prolifératives et inflammatoires
US20220119543A1 (en) * 2015-07-22 2022-04-21 Inatherys ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS
WO2020144233A1 (fr) * 2019-01-09 2020-07-16 Vect-Horus Molécules de liaison au récepteur de transferrine, leurs conjugués et leurs utilisations

Also Published As

Publication number Publication date
EP4626923A1 (fr) 2025-10-08
IL320972A (en) 2025-07-01
MX2025006221A (es) 2025-07-01
AU2023404617A1 (en) 2025-05-29
TW202440640A (zh) 2024-10-16
KR20250114322A (ko) 2025-07-29
JP2025539455A (ja) 2025-12-05
CN120282983A (zh) 2025-07-08

Similar Documents

Publication Publication Date Title
US20250034256A1 (en) Anti-pd-1 antibodies and uses thereof
KR102885855B1 (ko) 항-pd-1 항체 및 이의 용도
US20240002539A1 (en) Multispecific antibodies and uses thereof
US20240109963A1 (en) Multispecific antibodies and uses thereof
WO2021098851A1 (fr) Anticorps bispécifiques anti-ctla4/ox40 et leurs utilisations
WO2023143343A1 (fr) Anticorps anti-her2/trop2 et leurs utilisations
WO2024114687A1 (fr) Anticorps anti-tfr1 et leurs utilisations
WO2025180385A1 (fr) Anticorps anti-egfr/cd70 et leurs utilisations
WO2025061119A1 (fr) Anticorps anti-tigit et leurs utilisations
WO2025180305A1 (fr) Anticorps anti-psca et leurs utilisations
WO2023078450A1 (fr) Anticorps multispécifiques et leurs utilisations
WO2024175020A1 (fr) Anticorps anti-il2ra et leurs utilisations
WO2023241538A1 (fr) Anticorps anti-siglec15 et leurs utilisations
US20250270318A1 (en) Multispecific antibodies and uses thereof
AU2023329401A1 (en) Multispecific antibodies and uses thereof
HK40050386A (en) Anti-pd-1 antibodies and uses thereof
HK40050386B (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23896831

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 821564

Country of ref document: NZ

Ref document number: AU2023404617

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 320972

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/006221

Country of ref document: MX

Ref document number: 202380082014.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023404617

Country of ref document: AU

Date of ref document: 20231129

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2025531723

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025531723

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 821564

Country of ref document: NZ

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025011042

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517059052

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11202503666S

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202503666S

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202591733

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: MX/A/2025/006221

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2023896831

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202380082014.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023896831

Country of ref document: EP

Effective date: 20250702

WWP Wipo information: published in national office

Ref document number: 1020257018593

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202517059052

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2023896831

Country of ref document: EP